Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis

Exclusion Criteria

• •Subjects who had topical treatment with corticosteroids within 2 weeks before screening
• •Subjects who had systemic treatment with corticosteroids or ciclosporin and photopheresis treatment within 2 weeks before screening
• •Subjects who had ultraviolet irradiation within 2 weeks before screening
• •Subjects who participated in another drug trial within 4 weeks before screening
• •Subjects who have an allergy to one of the excipients
• •Female subjects who have a positive serum pregnancy test at screening, plan a pregnancy during study period, or are breast feeding
• •Female subjects who don't meet one of the following criteria: Be surgically sterile,Post-menopausal for at least 12 months, or If sexually active, they should use oral contraceptives, double barrier contraception, intrauterine device, or other methods approved by the sponsor
• •Subjects who have other topical treatment of the AD area
• •Subjects who take any systemic anti-infective or antibiotic treatment
• •Subjects who had eczema herpeticum
• •Subjects who have any clinically significant presence of skin disease or pigmentation other than atopic dermatitis, or wide scar on atopic dermatitis area
• •Subjects who have poorly-controlled chronic disease
• •Subjects who have significant medical problems, including but not limited to uncontrolled hypertension and congestive heart failure
• •Subjects who have clinically significant laboratory abnormalities at screening
• •Subjects who have a marked prolongation of QT/QTc interval at screening
• •Subjects who have a history of additional risk factors for TdP
• •Subjects who use a medication that prolongs the QT/QTc interval
• •Subjects who, in the opinion of the investigator, would be non-compliant with the visit schedule of study procedures